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INTRODUCTION
Lung cancer is one of the leading causes of cancer-related deaths in the world. Several areas of frequent allelic loss have been found in lung cancers (1) (2) (3) (4) . Recently, by a high-resolution, genome-wide search of loss of heterozygosity (LOH), new regions of allelic loss have been identified in lung cancers (5, 6) . Allelic loss at human chromosome 10q23-24 has been frequently observed in a variety of solid tumors containing lung cancer (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . The region is also known as a breakpoint region frequently detected in human leukemia cells (18) . Recently, the HELLS/SMARCA6 gene was identified on chromosome 10q24.2. SMARCA genes (SWI/SNF2-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A genes) are members of the SNF2 gene family. The SNF2 family members have helicase and ATPase activities, and are implicated in many features of cellular function, including chromatin remodeling, recombination, methylation and transcription (19) (20) (21) (22) . The multiple functions of SNF2 family members suggest that these genes may play important roles as tumor suppressor genes, similar to such genes as BRM/SMARCA2 (23) , BRG1/SMARCA4 (24, 25) , and HLTF/SMARCA3 (26) . BRM/SMARCA2 protein inhibited proliferation by binding with RB to induce cell cycle arrest (23) . Mutations of the BRG1/SMARCA4 gene were detected in prostate, breast, pancreas and lung cancer cell lines (24) , and it was shown that loss of BRG1/BRM was correlated with poor prognosis of lung cancer (25) . The HLTF/SMARCA3 gene has been reported to be a tumor suppressor gene candidate and a common target for gene silencing in colon cancers (26) . HELLS/SMARCA6 was first reported as a putative helicase in murine lymphocytes (27) . The helicase domains of HELLS/SMARCA6 closely resemble those of mammalian RAD54, another member of the SNF2 family, whose mutations are associated with tumorigenesis (28, 29) . Recently, it has been reported that HELLS/SMARCA6 plays an important role in DNA metabolism, cellular proliferation, CpG methylation and histone methylation (30) (31) (32) , and an alternatively spliced isoform of this gene has been implicated in leukemogenesis (33) . We analyzed expression of the HELLS/SMARCA6 gene in primary non-small cell lung cancers (NSCLCs) and found tumor-specific exon creation of the HELLS/SMARCA6 gene. Furthermore, we found prevalent loss of the HELLS/SMARCA6 locus in NSCLCs.
MATERIAL AND METHODS

Clinical samples
Surgically resected tissues from primary lung tumors and corresponding normal tissues were obtained from patients with lung tumors at Department of Surgical Oncology and Thoracic Surgery, Okayama University Hospital, after acquisition of written informed consent from all patients.
DNA and RNA extraction
Genomic DNAs were isolated from tumor and normal tissues by SDS/proteinase K treatment, phenol/chloroform extraction, and ethanol precipitation. Total RNAs were isolated from rapidly frozen samples by using ISOGEN reagent (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions.
Reverse transcription-PCR (RT-PCR) and cDNA sequencing
Oligo(dT)-primed cDNA was synthesized using the ReverTra Ace kit (Toyobo, Tokyo, Japan) 
Nested PCR analysis for alternative splicing variants
Each PCR product was cloned into pBluescript and sequenced. In order to define and screen the alternative splicing isoforms, nested RT-PCR was performed using the following primers: 
Loss of heterozygosity (LOH) analysis
To evaluate allelic loss at chromosome 10q23-24, highly polymorphic microsatellite markers D10S520 (about 60 kbp telomeric to the Hells), D10S1680 (about 700 kbp centromeric) and 10q23MS3 (about 600 kbp telomeric) were used. PCR primers for D10S520 and D10S1680 are available from the internet genome database (http://gdbwww.gdb.org). For the 10q23MS3 marker (GenBank accession number AB118108), forward primer 5'-CAA GGC ACT AAG CTC TGT ATT C and reverse primer 5'-TAT CCT GAC TGC CTG TGG TAG were used.
The forward primers were labeled with iodoacetamidofluorescein at the 5'-end and used for PCR. The PCR products were analyzed on a PRISM 3100 Analyzer with GeneScan Analysis software version 3.7 (Applied Biosystems). LOH was scored if one of heterozygous alleles showed at least 70% reduced intensity in tumor DNA as compared with the corresponding normal DNA.
Immunohistochemistory
Primary lung tumors fixed in 4% paraformaldehyde were embedded in paraffin and cut 5 μm increments. They were stained with hematoxylin and eosin, and immunostained with goat polyclonal antibody against carboxyl terminus of Lymphoid-Specific Helicase, Lsh/Hells (M-15, x100; Santa Cruz Biotechnology, Santa Cruz, CA) using avidin-biotin-horseradish peroxidase complex method (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA) with diaminobenzidine.
Statistical analysis
For analysis of relationship between clinical data and SMARCA6 variants, Fisher's exact test and Spearman's correlation coefficient test were used.
RESULTS
Expression of the Hells/SMARCA6 gene in NSCLCs
In order to identify the tumor suppressor genes for NSCLCs on chromosome 10q23-24, the 
Mutation analysis of the HELLS/SMARCA6 gene
We amplified the HELLS/SMARCA6 transcripts by RT-PCR with four pairs of primers to produce four fragments A, B, C and D, and sequenced these to find mutations in NSCLCs. No mutations were detected, but we found a single nucleotide polymorphism (SNP) at codon 77 (ATA or ATC) that yielded no amino acid change (data not shown).
Identification of 10 splicing variants of the HELLS/SMARCA6 gene
As RT-PCR and sequencing analyses of the HELLS/SMARCA6 gene suggested the existence of some splice variants, each fragment of the RT-PCR products from some of the tumor samples was cloned into plasmids and sequenced. We found ten alternatively spliced variants (Figures 1 and 2) .
Detection of splicing variants by nested PCR analysis
In order to analyze the expression of these splicing variants in NSCLCs and corresponding normal tissues, we performed RT-PCR analysis specific for each variant. Variant 1 was detected in 11 of 43 (26%) NSCLC tissues, however, interestingly, we could not find this variant in any of the 43 normal lung tissues we examined. Representative cases are shown in Figure 1D . We found a cryptic blanching point which has a conserved flanking sequence (ccctgac) identical to the consensus sequence, and a polypyrimidine tract located in the intron just before the 44-ntd sequence. No mutation was detected in the exon-intron boundary and intron 3. Furthermore, we analyzed expression level of the hnRNP A2 and B1 genes in NSCLC tissues by RT-PCR, as it has been reported on association of expression ratio of the hnRNP A2/B1 genes with RNA splicing error (34, 35) and association of the elevated hnRNP B1 mRNA level with human lung cancers (36) . However, the expression of hnRNP A2 and B1 was detected with similar level in tumor samples with and without variant 1, and no remarkable differences of expression level were detected between tumor and normal tissues (data not shown). We examined the relationship between the variant 1 expression and clinical data (Table I) . However, there was no significant correlation between the expression and the clinical data. The variant 1 was also found in 6 of 8 lung cancer cell lines (data not shown).
Other variants (2 to 10) were detected in both tumor and normal tissues. Detection frequency of the alternative variants and representative cases are shown in Figures 2 and 3 , respectively.
Loss of heterozygosity (LOH) around the HELLS/SMARCA6 gene
We analyzed allelic loss with 3 microsatellite markers at chromosome 10q23-24 in 37 primary NSCLCs along with corresponding normal lung tissues (Figure 4 ). Microsatellite marker D10S520, which is located near the HELLS/SMARCA6 gene, showed highly-frequent LOH in 11 of 27 (41%) informative cases. However, LOH with the flanking markers at a distance of about 700 kbp from D10S520 was shown in only 6 of 24 (25%) with centromeric marker D10S1680, and in only 9 of 29 (31%) with telomeric marker 10q23MS3. In particular, cases 117 and 119 showed LOH only at D10S520, and cases 195, 106, 134 and 140 exhibited common LOH at D10S520, suggesting the existence of tumor suppressor genes in this region.
Of 11 tumors that expressed the variant 1 of the HELLS/SMARCA6, 7 showed LOH (64%), 3
were non-informative, and only 1 sample showed retention of the D10S520 locus. There was no significant correlation between the expression level of the HELLS/SMARCA6 gene and allelic loss at D10S520.
Immunohistochemical analysis of HELLS/SMARCA6 expression
We examined the expression of HELLS/SMARCA6 protein in some specimens of NSCLCs with commercial antibody against the carboxyl terminal region ( Figure 5 ). In 5 cases of the tumor in which the variant 1 transcript was detected, the protein expression was almost same level as that of 5 tumor cases in which the variant 1 transcript was not detected. We found no difference of the immunostaining signal in the tumor and corresponding normal lung tissues.
DISCUSSION
In this study, we identified 10 splicing variants of the HELLS/SMARCA6 gene in NSCLCs. It is remarkable that variant 1, with a 44-ntd insertion between exons 3 and 4, was detected exclusively in tumor samples (26%, 11/43 cases) but not in corresponding normal tissues.
There were no registered expressed sequence tags (EST) harboring the 44-ntd sequence in the NCBI hEST database, indicating that the 44-ntd is a truly intronic sequence. A cryptic blanching point and polypyrimidine tract, which we detected in intron upstream of the 44-ntd insertion, might be used for formation of splicing lariat structure upon the alternative splicing.
Previous results, that this protein is required for normal CpG methylation and is crucial for formation of normal histone methylation (31, 32) , and our results, that showed the frequent loss of this locus, suggest that this gene product may normally function as a tumor suppressor.
As the variant 1 mRNA is expected to produce a prematurely-terminated polypeptide of 97 amino acid residues, the peptide may function in a dominant-negative manner against the normal HELLS/SMARCA6 protein (838 aa). It may be supported by the recent report that the nuclear localization domain of this protein is located between at least amino acids 31 and 176 (37) . It will be desired to perform transfection experiments with the variant 1 and/or fulllength HELLS/SMARCA6 cDNA expression vectors, and the protein expression analysis with customized HELLS/SMARCA6 antibodies, in order to clarify these unsolved issues.
Confirmation of the variant 1 protein by western blotting was not performed, because the commercial antibody was made against the carboxyl terminal region of HELLS/SMARCA6.
The hnRNP A2 and B1 genes have been reported to be involved in RNA splicing, transport (34, 35) , and are associated with human lung cancers (36) . Therefore, we analyzed the ratio of hnRNP A2/B1 gene expression in NSCLCs. However, the expression was at almost the same level in most samples, suggesting that the expression of the hnRNP A2 and B1 genes is not correlated with the production of variant 1. However, we can not exclude the possibility that the up-regulation of hnRNPA2/B1 occurs at the post-transcriptional level (38) .
It has been reported that the alternative isoform with 75-ntd deletion in exon18 (variant 9) was detected in 57% of acute myelogenous leukemias and 37% of acute lymphoblastic leukemias, but was not in ovarian caricinomas and normal tissues containing thymus, bone marrow, peripheral blood mononuclear cells, testis, ovary and lymph node (33) . In the present study, the variant 9 was detected in 7 of 37 (19%) primary lung tumors and in 5 of 37 (14%) normal lung tissues. These results suggest that the normal lung tissues in our cases may be already affected by initiation of tumorigenesis like field cancerization, or that the variant 9 may be expressed in some normal tissues containing lung. Defining the expression pattern in other tissues will be also required for further analyses.
Our results reveal an association of the splicing variant 1 of the HELLS/SMARCA6 gene with a considerable subset of NSCLC by a novel "exon-creation" mechanism for gene inactivation. To our knowledge, there are few descriptions of such a mechanism relevant to tumorigenesis with high frequency, though it has been reported that cryptic exons are involved in the activation of the EWS-FLI1 chimeric gene in Ewing sarcomas (39) . Although it is possible that progression of lung cancer leads to a disturbance of splicing machinery and produces alternatively spliced variants in a tumor-specific manner, the tumor-specific variant 1 could be useful as a tumor marker for NSCLCs. Further study, including a functional analysis, will be required to uncover the role of this variant in the tumorigenesis of the lung epithelium. 
